Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Sweeney

Showing results (11-20 of 97) with videos related to

Pageof 10
Sort By:
Expert Review of Anticancer Therapy|October 30, 2014
'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancerMark Voskoboynik, John Staffurth, Zafar Malik, et al.
Prostate Cancer and Prostatic Diseases|December 22, 2017
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivationMegan McNamara, Christopher Sweeney, Emmanuel S Antonarakis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2019
Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the CartNeha Vapiwala, Michael S Hofman, Declan G Murphy, et al.
Pediatric Blood & Cancer|May 9, 2019
AYA testis cancer: The unmet challengeSara Stoneham, Matthew Murray, Benjamin Thomas, et al.
European Urology|April 10, 2025
Reply to Felix Melchior, Andreas Pircher, and Isabel Heidegger's Letter to the Editor re: Johann S. de Bono, Meng He, Chen Shi, et al. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol. 2025;87:468-75Christopher Sweeney, Meng He, Matthew Wongchenko, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 29, 2020
A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancerMichael J Kucharczyk, Jonathan So, Gwenaelle Gravis, et al.
Abdominal Imaging|November 30, 2014
Approach to risk stratification in testicular germ cell tumors: a primer for radiologistsMonica J Wood, Sree Harsha Tirumani, Christopher Sweeney, et al.
Clinical Genitourinary Cancer|August 31, 2017
Smoking and Disease Outcomes in Patients With Malignant Germ Cell TumorsElizabeth O'Donnell, Sarah C Markt, Rowan Miller, et al.
Prostate Cancer and Prostatic Diseases|September 5, 2020
Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastasesBradley McGregor, Li Zhang, Kathryn P Gray, et al.
Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine|September 24, 2015
Relationship Between the Pathologic Subtype/Initial Stage and Microliths in Testicular Germ Cell TumorsFarhana Sharmeen, Michael H Rosenthal, Monica J Wood, et al.
Pageof 10

Showing results (11-20 of 97) with videos related to

Sort By:
Pageof 10
Expert Review of Anticancer Therapy|October 30, 2014
'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancerMark Voskoboynik, John Staffurth, Zafar Malik, et al.
Prostate Cancer and Prostatic Diseases|December 22, 2017
The evolving landscape of metastatic hormone-sensitive prostate cancer: a critical review of the evidence for adding docetaxel or abiraterone to androgen deprivationMegan McNamara, Christopher Sweeney, Emmanuel S Antonarakis, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 23, 2019
Strategies for Evaluation of Novel Imaging in Prostate Cancer: Putting the Horse Back Before the CartNeha Vapiwala, Michael S Hofman, Declan G Murphy, et al.
Pediatric Blood & Cancer|May 9, 2019
AYA testis cancer: The unmet challengeSara Stoneham, Matthew Murray, Benjamin Thomas, et al.
European Urology|April 10, 2025
Reply to Felix Melchior, Andreas Pircher, and Isabel Heidegger's Letter to the Editor re: Johann S. de Bono, Meng He, Chen Shi, et al. Final Overall Survival and Molecular Data Associated with Clinical Outcomes in Patients Receiving Ipatasertib and Abiraterone in the Phase 3 IPATential150 Trial. Eur Urol. 2025;87:468-75Christopher Sweeney, Meng He, Matthew Wongchenko, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|August 29, 2020
A combined biological and clinical rationale for evaluating metastasis directed therapy in the management of oligometastatic prostate cancerMichael J Kucharczyk, Jonathan So, Gwenaelle Gravis, et al.
Abdominal Imaging|November 30, 2014
Approach to risk stratification in testicular germ cell tumors: a primer for radiologistsMonica J Wood, Sree Harsha Tirumani, Christopher Sweeney, et al.
Clinical Genitourinary Cancer|August 31, 2017
Smoking and Disease Outcomes in Patients With Malignant Germ Cell TumorsElizabeth O'Donnell, Sarah C Markt, Rowan Miller, et al.
Prostate Cancer and Prostatic Diseases|September 5, 2020
Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastasesBradley McGregor, Li Zhang, Kathryn P Gray, et al.
Journal of Ultrasound in Medicine : Official Journal of the American Institute of Ultrasound in Medicine|September 24, 2015
Relationship Between the Pathologic Subtype/Initial Stage and Microliths in Testicular Germ Cell TumorsFarhana Sharmeen, Michael H Rosenthal, Monica J Wood, et al.
Pageof 10